Seminars in Oncology
Volume 35, Issue 3 , Pages 221-228 , June 2008

Induction Therapy in the Modern Era of Combined-Modality Therapy for Locally Advanced Head and Neck Cancer

  • Marshall Posner

      Affiliations

    • Head and Neck Oncology Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
    • Corresponding Author InformationAddress correspondence to Marshall Posner, MD, Director, Head and Neck Oncology Program, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney St, W430 Boston, MA 02115.
    • ,
  • Jan B. Vermorken

      Affiliations

    • Department of Medical Oncology, University Hospital Antwerp, Edegem, Belgium.

References 

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66
  2. IARC. Globocan 2002. www dep.iarc.fr
  3. Adelstein D, Li Y, Adams G, et al. An Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92–98
  4. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004;22:69–76
  5. Forastiere A, Maor M, Weber R, Pajak T, et al. Long term results of Intergroup RTOG 91-11: a phase III trial to preserve the larynx—induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. [abstract] Proc Am Soc Clin Oncol. 2006;5517
  6. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–578
  7. Lefebvre J, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European organization for research and treatment of cancer phase III trial. J Natl Cancer Inst. 1996;88:890–898
  8. Ang KK, Harris J, Garden AS, et al. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation Therapy Oncology Group phase II trial 99-14. J Clin Oncol. 2005;23:3008–3015
  9. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945–1952
  10. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937–1944
  11. Semrau R, Mueller RP, Stuetzer H, et al. Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2006;64:1308–1316
  12. Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy—results of a multicentric randomized German trial in advanced head and neck cancer. Int J Radiat Oncol Biol Physics. 2001;50:1161–1171
  13. Pignon J, Bourhis J, Domenge C, Designe L MACH-NC Collaborative Group. Chemotherapy added to locoregional treatment for head and neck squamous-cell cancer: three meta-analysis of updated individual data. Lancet. 2000;355:949–955
  14. Monnerat C, Faivre S, Temam S, Bourhis J, Raymond E. End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann Oncol. 2002;13:995–1006
  15. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91:2081–2086
  16. Kish J, Ensley J, Jacobs J, Binns P, Al-Sarraf M. Evaluation of high-dose cisplatin and 5-FU infusion as initial therapy in advanced head and neck cancer. Am J Clin Oncol. 1988;11:553–557
  17. Domenge C, Hill C, Lefebvre J, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. Br J Cancer. 2000;83:1594–1598
  18. Paccagnella A, Orlando A, Marchiori C, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst. 1994;86:265–272
  19. Lefebvre J, Chevalier D, Luboinski B, et al. Is laryngeal preservation with induction chemotherapy safe in the treatment of hypopharyngeal SCC? (Final results of the phase III EORTC 24891). [abstract] Proc Am Soc Clin Oncol. 2004;23:5531
  20. Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324:1685–1689
  21. Lefebvre J, Horiot J, Rolland F, et al. Phase III study on larynx preservation comparing induction chemotherapy and radiotherapy versus alternating chemoradiotherapy in resectable hypopharynx and larynx cancers (EORTC protocol 24954–22950). [abstract] Proc Am Soc Clin Oncol. 2007;25:LBA 6016
  22. Forastiere A. Paclitaxel (Taxol) for the treatment of head and neck cancer. Semin Oncol. 1994;21(Suppl 8):49–52
  23. Catimel G, Verweij J, Mattijsen V, et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol. 1994;5:553-37
  24. Dreyfuss A, Clark J, Norris C, et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol. 1996;14:1672–1678
  25. Colevas A, Busse P, Norris C, et al. Induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil, and leucovorin (TPFL5) for squamous cell carcinoma of the head and neck: a phase I/II trial. J Clin Oncol. 1998;16:1331–1339
  26. Colevas A, Norris C, Tishler R, et al. A phase II trial of TPFL (docetaxel, cisplatin, 5-fluorouracil, leucovorin) as induction for squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 1999;17:3503–3511
  27. Colevas AD, Norris CM, Tishler RB, et al. Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN). Am J Clin Oncol. 2002;25:153–159
  28. Posner MR, Glisson B, Frenette G, et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2001;19:1096–1104
  29. Schrijvers D, Van Herpen C, Kerger J, et al. Docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study. Ann Oncol. 2004;15:638–645
  30. Haddad R, Colevas AD, Tishler R, et al. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer. 2003;97:412–418
  31. Calais G, Pointreau Y, Alfonsi M, et al. Randomized phase III trial comparing induction chemotherapy using cisplatinum, fluorouracil with or without docetaxel for organ preservation in hypopharynx and larynx cancer (Preliminary results of GORTEC 2000-01). [abstract] Proc Am Soc Clin Oncol. 2006;24:5506
  32. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:1705–1715
  33. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357:1695–1704
  34. Bernier J, Coens C, Remenar E, et al. Impact on quality of life (QoL) of the addition of docetaxel (T) to neoadjuvant cisplatin plus 5-fluorouracil treatment in patients with locally advanced unresectable squamous cell carcinoma of the head and neck: EORTC study 24971. [abstract 5522] J Clin Oncol. 2006;24(Suppl 18):285s
  35. Zorat PL, Paccagnella A, Cavaniglia G, et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst. 2004;96:1714–1717
  36. Taylor S, Murthy A, Vannetzel J, et al. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol. 1994;12:385–395
  37. Specenier PM, Vermorken JB. Neoadjuvant chemotherapy in head and neck cancer: should it be revisited?. Cancer Lett. 2007;256:166–177
  38. Hitt R, Grau J, Lopez-Pousa A, et al. Randomized phase I/II clinical trial of induction chemotherapy with either cisplatin/5-fluorouracil (PF) or docetaxel/cispaltin/5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) v CRT alone form patients with unresectable locally advanced head and neck cancer. [abstract 5515] J Clin Oncol. 2006;24(Suppl 18):283s
  39. Ringstrom E, Peters E, Hasegawa M, Posner M, Liu M, Kelsey KT. Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res. 2002;8:3187–3192

PII: S0093-7754(08)00070-5

doi: 10.1053/j.seminoncol.2008.03.007

Seminars in Oncology
Volume 35, Issue 3 , Pages 221-228 , June 2008

Article Tools